Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.
about
New Is Old, and Old Is New: Recent Advances in Antibiotic-Based, Antibiotic-Free and Ethnomedical Treatments against Methicillin-Resistant Staphylococcus aureus Wound InfectionsUpdate on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic optionsVancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal managementCoagulase-negative staphylococci.Description and validation of a spectrum score method to measure antimicrobial de-escalation in healthcare associated pneumonia from electronic medical records data.Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitals.[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Bacterial Epidemiology and Antimicrobial Resistance in the Surgery Wards of a Large Teaching Hospital in Southern Italy.Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013).Prevalence and Trends of Staphylococcus aureus Bacteraemia in Hospitalized Patients in South Africa, 2010 to 2012: Laboratory-Based Surveillance Mapping of Antimicrobial Resistance and Molecular Epidemiology.Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial DominancePolymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens.Results from the Canadian Nosocomial Infection Surveillance Program on Carbapenemase-Producing Enterobacteriaceae, 2010 to 2014.Pathogens and antimicrobial susceptibility profiles in critically ill patients with bloodstream infections: a descriptive study.In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario.Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL.Genomic tools to profile antibiotic mode of action.Infections Caused by Stenotrophomonas maltophilia in Recipients of Hematopoietic Stem Cell Transplantation.Tetracycline Antibiotics and Resistance.Colistin: still a lifesaver for the 21st century?Structure-activity relationships in ultrashort cationic lipopeptides: the effects of amino acid ring constraint on antibacterial activity.Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity.Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.The Effects of Berberine and Palmatine on Efflux Pumps Inhibition with Different Gene Patterns in Pseudomonas aeruginosa Isolated from Burn Infections.Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.Molecular characterization of methicillin-resistant Staphylococcus aureus resistant to tigecycline and daptomycin isolated in a hospital in Brazil.Amphiphilic lysine conjugated to tobramycin synergizes legacy antibiotics against wild-type and multidrug-resistant Pseudomonas aeruginosa.Fitness tradeoffs of antibiotic resistance in extra-intestinal pathogenic Escherichia coli.Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.Validation of the prediction rules identifying drug-resistant pathogens in community-onset pneumonia
P2860
Q26749376-B831379B-4637-49FF-97C0-1B1DB5CC87C0Q26782924-F4404F22-6576-49FE-9EAB-108208E03FCBQ26798630-C6675450-E340-4580-A893-D498607451ABQ30401758-C6880D1E-CE13-4A02-97F8-153B71A5A04FQ30647100-B50D1E9D-2FD8-47B6-B5AF-BF5A4A1D8297Q34513298-B24B7A1F-0CD6-4F87-BA6A-5CD33BCE4511Q34677611-DA3FF257-695D-4B21-8FEE-4E9A0302C35BQ35607775-858B531D-9857-49C9-8C72-B8F42CAD10B0Q35619094-0104F470-6430-4A31-A771-C2619DD0189AQ35669939-55D0746E-DDDD-41EE-887C-CBB5462C725CQ35746080-9C9541EA-BE0F-464A-A154-4A631FD18891Q35882454-8FC740FF-A0F3-4ACD-B0F8-11461E48C9DAQ36076066-D1528752-4B9A-41F0-9169-DFB03B5FC773Q36915742-6F347F70-EFE9-4793-9D6D-48EE8403FF85Q37358700-2BF3BBB3-4985-4863-82F8-39F40020C113Q37521007-254789D6-E67A-4C10-8EBA-963D93DC1F61Q37544647-DB3F293F-3AD7-4CF9-B531-C4A16E51F6CCQ37681591-13C1619C-2478-44AE-A9DB-CC7148053F9CQ38164663-8EB8626E-44AB-4C33-8EFF-4B4B18C0115AQ38195069-DFD21FC0-DC3E-44E5-9C1B-3F3FAE0451FBQ38247296-DEB3281B-1010-48D1-840F-E46DF4CC00EEQ38779243-F5C26E16-AC76-4312-AF91-B43C3F5B37FCQ38940249-D16F0C56-04D0-4E9F-A5F4-525D028F06F4Q38970950-80D7C746-25B8-4086-AC06-DAEAA19EF119Q39026738-7D75EE8F-4BE8-46A5-A7B9-980F2E9BC8A9Q39597152-A2BE9023-D5BB-4CEF-9911-DF6EBF42EEC4Q40155946-B08B18E6-31DF-401F-8F39-4D62AEA32F08Q40370889-62EA45DF-57E2-468B-82E1-3F65B26A5E22Q40617761-71D2F92B-8140-4A18-A7D8-E7BF2B5752ECQ40697349-65F4EB86-BEB7-4161-B478-8FE109E9C2DFQ41172790-063B7AB0-56AA-4A16-90F7-DB917DCE4BB5Q46319164-329E7E7B-C781-4D8F-8659-22A2759CC1A0Q48181255-8B003FA0-BBB3-4B3B-8B6F-D576323A42E4Q50047143-E410D97C-4C5E-44CD-BE8E-F96CE7BA5756Q50053159-74AABB62-327C-44A7-A462-9923B1FE0685Q57815893-DA2C011E-3D6E-4124-90F3-99473254802E
P2860
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Antimicrobial susceptibility o ...... of the CANWARD 2007-11 study.
@en
Antimicrobial susceptibility o ...... of the CANWARD 2007-11 study.
@nl
type
label
Antimicrobial susceptibility o ...... of the CANWARD 2007-11 study.
@en
Antimicrobial susceptibility o ...... of the CANWARD 2007-11 study.
@nl
prefLabel
Antimicrobial susceptibility o ...... of the CANWARD 2007-11 study.
@en
Antimicrobial susceptibility o ...... of the CANWARD 2007-11 study.
@nl
P2093
P356
P1476
Antimicrobial susceptibility o ...... of the CANWARD 2007-11 study.
@en
P2093
Andrew J Denisuik
Andrew Walkty
Canadian Antimicrobial Resistance Alliance
Daryl J Hoban
Frank Schweizer
Heather J Adam
James A Karlowsky
Jeff Fuller
Kimberly A Nichol
Melanie R Baxter
P356
10.1093/JAC/DKT022
P407
P478
68 Suppl 1
P577
2013-05-01T00:00:00Z